Cerevel Therapeutics Holdings, Inc. (CERE)
NASDAQ: CERE · IEX Real-Time Price · USD
43.23
+0.53 (1.24%)
Jul 22, 2024, 9:30 AM EDT - Market open

CERE Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Net Income
-460.47-432.84-351.51-225.33-148.27-128.39
Depreciation & Amortization
5.855.634.92.730.40.18
Share-Based Compensation
77.7569.4138.7823.9410.528.31
Other Operating Activities
9.8215.514.6420.1223.4249.18
Operating Cash Flow
-367.05-342.3-293.19-178.55-117.8-70.72
Capital Expenditures
-3.74-3.81-3.95-10.5-18.89-1.1
Change in Investments
-14.1577.53-384.88-425.1600
Investing Cash Flow
-17.973.72-388.83-435.66-18.89-1.1
Share Issuance / Repurchase
520.41517.51251.32337.1442.6260.06
Debt Issued / Paid
31.2531.25372.2731.2500
Other Financing Activities
--0.14-0.455.25-1.78-
Financing Cash Flow
551.66548.62623.19423.6440.8460.06
Net Cash Flow
166.71280.04-58.83-190.61304.14-11.76
Free Cash Flow
-370.79-346.11-297.14-189.05-136.69-71.82
Free Cash Flow Per Share
-2.04-2.14-1.96-1.38-1.86-1.63
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).